March 2024
-
03.12.2024 Medicines Research Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
November 2023
-
11.02.2023 Research and Pipeline Research Pfizer Highlights Scientific Advances from Growing Hematology Portfolio at American Society of Hematology Annual Meeting
June 2023
-
06.26.2023 Research and Pipeline Research Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus -
06.01.2023 Research and Pipeline Research Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options
December 2022
-
12.29.2022 Medicines Research Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate -
12.01.2022 Financial Finance Medicines Research Vaccines Pfizer Invites Public to Register for Webcast of Pfizer Near-Term Launches + High-Value Pipeline Day -
12.01.2022 Vaccines Research Vaccines Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate
October 2022
-
10.04.2022 Research and Pipeline Research Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial
September 2022
-
09.19.2022 Research and Pipeline Research Vaccines Pfizer Announces Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union -
09.14.2022 Research and Pipeline Research Pfizer Initiates Phase 3 Study of mRNA-Based Influenza Vaccine
August 2022
-
08.08.2022 Research and Pipeline Research Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15